Novartis AG Receivables 2010-2024 | NVS

Novartis AG receivables for the quarter ending September 30, 2024 were $8.150B, a 14.8% increase year-over-year.

  • Novartis AG receivables for 2023 were $7.533B, a 9.61% decline from 2022.
  • Novartis AG receivables for 2022 were $8.334B, a 0.62% increase from 2021.
  • Novartis AG receivables for 2021 were $8.283B, a 2.05% decline from 2020.

Novartis AG Receivables 2010-2024 | NVS

  • Novartis AG receivables for 2023 were $7.533B, a 9.61% decline from 2022.
  • Novartis AG receivables for 2022 were $8.334B, a 0.62% increase from 2021.
  • Novartis AG receivables for 2021 were $8.283B, a 2.05% decline from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$692.7B
Novo Nordisk (NVO)$460.6B
Johnson & Johnson (JNJ)$368.4B
AbbVie (ABBV)$294.4B
Merck (MRK)$244.2B
AstraZeneca (AZN)$197.8B
Pfizer (PFE)$142.2B
Sanofi (SNY)$121.8B
Innoviva (INVA)$1.2B